

## October 12, 2021

## Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 12, 2021-- <u>Veracyte, Inc</u>. (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2021 after the close of market on Tuesday, November 9. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company's website and will be available via the following link: <a href="https://edge.media-server.com/mmc/p">https://edge.media-server.com/mmc/p</a> (3rcxuu6u. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company's website at <a href="https://investor.veracyte.com/events-presentations">https://investor.veracyte.com/events-presentations</a>.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):	(855) 541-0980
International participant dial-in number:	(970) 315-0440
Conference I.D.:	9065288

## About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit <u>www.veracyte.com</u> and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006039/en/

## **Investor and Media Contact:**

Tracy Morris Vice President of Corporate Communications & Investor Relations 650-380-4413 tracy.morris@veracyte.com

Source: Veracyte, Inc.